BioNTech vs Exelixis
BNTX and EXEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNTX and EXEL compare
Exelixis grew revenue faster over the last twelve months (9.1% versus 4.3% for BioNTech).
Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with −39.6% at BioNTech.
Exelixis scores higher on the StockData Score (17 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNTX | EXEL |
|---|---|---|
| Size and price | ||
| Market cap | – | $17.2B |
| Share price | $88.17 | $69.39 |
| Change, 1 year | −14.7% | 76.0% |
| Change, 5 years | −59.3% | 258% |
| Beta (5Y) | 0.82 | 0.74 |
| Employees | 500 | 1,077 |
| StockData Score | ||
| Total score | 3 | 17 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 6 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 20.8× |
| P/S | – | 6.9× |
| P/B | – | 9.4× |
| EV/EBITDA | – | 15.8× |
| P/FCF | – | 14.8× |
| PEG | – | 0.29 |
| FCF yield | – | 6.8% |
| Fair value | – | $64.67 |
| Margin of safety | – | −7.3% |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 9.1% (better) |
| Revenue growth, 5Y average | 42.9% (better) | 18.6% |
| Net income growth (TTM) | – | 30.6% |
| EPS growth (TTM) | – | 40.9% |
| EPS growth, 5Y average | – | 51.4% |
| Profitability | ||
| Gross margin | 77.6% | 96.3% (better) |
| Operating margin | −49.0% | 40.2% (better) |
| Net margin | −39.6% | 35.5% (better) |
| FCF margin | 9.8% | 46.5% (better) |
| Return on equity | – | 44.3% |
| Return on invested capital | – | 75.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −20.1× | – |
| Current ratio | 7.54 (better) | 3.21 |
| Altman Z-score | – | 17.78 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 7.3% |
| Shareholder yield | – | 7.3% |
| Ownership | ||
| Held by institutions | 18.9% | 105% |
| Held by insiders | 58.1% | 9.7% |
| Insider net buying, 12 months | −$69.2M | −$41.1M (better) |
| Short interest, % of float | – | 12.6% |
Go deeper
- BNTX stock overview
- BNTX income statement
- BNTX valuation and score
- EXEL stock overview
- EXEL income statement
- EXEL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.